Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

6082 ARTÍCULOS , VIENDO DEL 4021 AL 4035

The NLRP3-α-Synuclein Circuit: A Core Driver and Therapeutic Target in Parkinson's Disease

Liu K, He Z, Zhang L, Wu YM, Xiao L.

J Inflamm Res. 2026 May 28;19:597280. doi: 10.2147/JIR.S597280. eCollection 2026.

Parkinson's Disease: Conventional Pharmacotherapy, Drug Delivery Innovations, and Emerging Therapeutic Targets

Raina D, Marwah C, Singh S, Akhtar A.

Brain Sci. 2026 Feb 14;16(2):226. doi: 10.3390/brainsci16020226.

The central cholinergic system as a therapeutic target in Parkinson's disease

Miller SJ, Yue JS, Bozal SB, Logan R, Hafler BP.

J Parkinsons Dis. 2026 May;16(3):391-415. doi: 10.1177/1877718X261427270. Epub 2026 Mar 19.

Copper Dyshomeostasis Affects α-Synuclein Clearance Mechanisms in Parkinson's Disease: Insights from In Vitro Models and Translational Evidence

Musarò D, Greco M, Lanza M, Damato M, Maffia M.

Int J Mol Sci. 2026 Mar 25;27(7):2993. doi: 10.3390/ijms27072993.

Interaction between Poly(ADP-ribose) polymerase-1 and α-synuclein pathology in Parkinson's disease

Zhang P, Li Q, Diao X, Zeng S.

Front Neurosci. 2026 Apr 13;20:1774158. doi: 10.3389/fnins.2026.1774158. eCollection 2026.

cGAS-STING activation in Parkinson's Disease: From mechanisms to Disease-Modifying therapeutic strategies

Solomon J, Mandal S, Aran KR.

Gene. 2026 Apr 5;985:150000. doi: 10.1016/j.gene.2026.150000. Epub 2026 Jan 5.

DYRK1A and Parkinson's disease, facts and hypotheses

Meijer L, Lindberg MF, Hogrel G, Khor B.

Neurobiol Dis. 2026 Apr 14;225:107379. doi: 10.1016/j.nbd.2026.107379. Online ahead of print.

Parkinson's disease as a disorder of synaptic raft integrity: A unified explanation for motor subtypes and non-motor symptoms

Sakoda S.

Neurochem Int. 2026 May 14;197:106177. doi: 10.1016/j.neuint.2026.106177. Online ahead of print.

Bibliometric analysis of the pathogenesis of Parkinson's Disease

Feng Y, Wang K, Guo X, Guo H, Gao X.

Pathol Res Pract. 2026 May;281:156417. doi: 10.1016/j.prp.2026.156417. Epub 2026 Feb 21.

Advancing personalized medicine for Parkinson's disease: transforming treatment and therapeutic outcomes

Swathi M, Bedadakota SS, Animish A, Suthindhiran K, Jayasri MA.

3 Biotech. 2026 Apr;16(4):127. doi: 10.1007/s13205-025-04674-y. Epub 2026 Mar 9.

LRRK2 and GBA1 in Lewy body diseases: neuropathological subtypes at opposite ends of a spectrum?

Jha V, Kalia LV.

Mol Neurodegener. 2026 Apr 27. doi: 10.1186/s13024-026-00939-z. Online ahead of print.

Association of telomere length with cognitive function and dementia: A cross-sectional NHANES analysis and 2-sample Mendelian randomization study

Shen Y, Zhou J, Sun B, Geng L.

Medicine (Baltimore). 2026 Apr 10;105(15):e48217. doi: 10.1097/MD.0000000000048217.

Engineered Exosomes: Innovative Strategies for Precision Drug Delivery in Parkinson's Disease

Yuan X, Wang C, Yan J, Wang J, Li F, You Y, Qi Z.

Mol Neurobiol. 2026 May 13;63(1):626. doi: 10.1007/s12035-026-05898-6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias